5-AMINO-1MQ Why NNMT Inhibition Is Gaining Attention in Metabolic Research

5-AMINO-1MQ Why NNMT Inhibition Is Gaining Attention in Metabolic Research

ACL Premium Research Products

5-AMINO-1MQ Why NNMT Inhibition Is Gaining Attention in Metabolic Research

A scientific overview with every key concept translated into plain English

Preclinical Research Research Use Only Scientific Education

Why researchers are paying attention

5-Amino-1MQ is short for 5-amino-1-methylquinolinium and is also written as 5A1MQ or 5-AMQ in scientific papers. It is a small molecule that inhibits the enzyme nicotinamide N-methyltransferase, better known as NNMT. Although it is sometimes grouped with peptides in online discussions, 5-amino-1MQ is not a peptide. It is a quinolinium compound.

Interest in 5-amino-1MQ comes from the biology of its target. NNMT sits at an intersection between nicotinamide metabolism, the NAD+ salvage pathway, cellular methyl donor balance, adipocyte biology, and metabolism in skeletal muscle. That makes NNMT inhibition a useful way to investigate how one enzyme can influence several connected metabolic systems.

In Plain English

5-Amino-1MQ interests researchers because it blocks a specific metabolic enzyme. That enzyme helps decide how cells use certain raw materials involved in energy processing and chemical signaling. By partially turning down that enzyme in a controlled experiment, researchers can observe what changes elsewhere in the cell.

The important distinction is that 5-amino-1MQ is a research tool with promising preclinical findings, not a clinically established intervention.

What does NNMT do?

NNMT transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH).

Nicotinamide + SAM β†’ 1-MNA + SAH

This reaction matters because nicotinamide can also be recycled through the NAD+ salvage pathway. NAD+ is an essential cellular cofactor involved in redox chemistry, energy metabolism, DNA repair signaling, and other enzyme systems. SAM, meanwhile, is a major methyl donor used in many cellular reactions.

NNMT therefore does more than produce 1-MNA. Its activity can influence the availability of nicotinamide and SAM, potentially affecting metabolism related to NAD+, methylation chemistry, polyamine flux, and gene regulation. These effects are highly dependent on tissue, model, and biological context. NNMT should not be described simply as a β€œbad” enzyme.

In Plain English

Think of nicotinamide and SAM as two supplies that a cell can send down different production lines. NNMT uses some of both supplies to make 1-MNA. When NNMT activity is reduced, the cell may have more opportunity to use those supplies elsewhere, including pathways connected with NAD+ and methylation.

That does not mean every cell or tissue will respond in the same way. It means NNMT is a strategically located metabolic β€œtraffic controller” worth studying.

What has 5-amino-1MQ done in cell research?

The foundational 2018 study characterized 5-amino-1MQ as an inhibitor capable of crossing cell membranes and targeting the region of NNMT that binds nicotinamide. The compound showed biochemical potency in the low micromolar range and did not significantly inhibit the related methyltransferases or NAD+ salvage enzymes included in the study’s selectivity panel.

In cultured mouse adipocytes, 5-amino-1MQ reduced intracellular 1-MNA, providing evidence of target engagement inside the cells. Investigators also reported reduced lipogenesis and increases in intracellular NAD+ and SAM under selected experimental conditions. These findings linked NNMT inhibition to measurable changes in both the target pathway and downstream adipocyte metabolism. Neelakantan et al., Biochemical Pharmacology (2018)

In Plain English

In fat cells grown in a laboratory, researchers found signs that 5-amino-1MQ reached its intended target and reduced the amount of lipid the cells were producing under the study conditions. The cells also showed changes in molecules connected with energy handling and methyl donor chemistry.

This is encouraging mechanistic evidence, but cultured cells are a simplified model. They cannot establish what will happen in an intact animal or in a person.

What has been observed in metabolic animal models?

Early work in mice made obese through diet found that systemic 5-amino-1MQ treatment reduced body weight gain, the mass of white adipose tissue, adipocyte size, and total plasma cholesterol without reducing total food intake during the study. This suggested that the observed changes were not explained simply by the animals eating less. Neelakantan et al., Biochemical Pharmacology (2018)

A 2021 study then examined NNMT inhibition alongside a switch to a diet with fewer calories in obese mice. Compared with diet change alone, the combined intervention produced larger and more persistent reductions in body weight and fat mass, improved the ratio of lean mass to body weight, and reduced measurements in the liver and white adipose tissue. Liver fat and steatosis measurements also moved closer to those of lean control animals. Sampson et al., Scientific Reports (2021)

In 2024, a mouse study lasting 28 days added further detail. 5A1MQ produced a response that varied with dose. It limited gains in body weight and fat mass, improved glucose tolerance and measurements of insulin sensitivity, reduced hyperinsulinemia, and improved several liver findings. These findings included steatosis, macrophage infiltration, liver triglycerides, and circulating markers associated with liver stress. The study also demonstrated distribution to metabolically active tissues after controlled subcutaneous administration. Babula et al., Diabetes, Obesity and Metabolism (2024)

In Plain English

Across several mouse studies, NNMT inhibition was associated with favorable changes in fat tissue, body composition, glucose handling, and liver measurements. In the first study, the mice did not simply eat less, which made the metabolic findings more interesting. In another study, NNMT inhibition appeared to complement a diet change rather than replace it.

These are positive preclinical signals. They do not prove benefits related to body weight, blood sugar, or liver function in humans.

Why skeletal muscle researchers are interested

Research interest in 5-amino-1MQ has expanded beyond adipocyte biology. In a 2019 study, aged mice underwent a controlled protocol involving acute muscle injury. Treatment with the NNMT inhibitor increased the proliferation and fusion of muscle stem cells. It also supported almost twice as much regenerated myofiber area and increased peak torque by approximately 70% compared with controls. Related experiments in cell culture showed enhanced myoblast differentiation with changes in the NAD+/NADH redox state. Neelakantan et al., Biochemical Pharmacology (2019)

A separate 2024 investigation used both induced aging and naturally aged mouse models. NNMT inhibition improved measurements of grip strength, reduced the decline in whole body lean mass index, increased selected measurements of muscle mass, and was associated with higher muscular NAD+, PGC-1Ξ±, and phosphorylated AMPK. Liang et al., Aging Cell (2024)

More recently, a 2025 mouse study of experimental hindlimb ischemia used the same 5-amino-1MQ iodide research compound. NNMT inhibition improved strength, power, and total work in the ischemic limb without significantly changing blood flow recovery or capillary density. That result was especially useful mechanistically because it suggested a direct effect on muscle in that model rather than an effect explained by improved perfusion. Dong et al., Physiological Reports (2025)

In Plain English

In controlled mouse models of aging, injury, and reduced limb blood flow, researchers observed stronger functional or regenerative muscle outcomes after NNMT inhibition. The 2025 study was notable because muscle performance improved even though blood flow recovery did not. This gave researchers a more focused clue about where the effect may have occurred.

This should be described as preclinical muscle and regeneration research, not as evidence for bodybuilding, athletic enhancement, injury treatment, or therapies for age related conditions in people.

Pharmacokinetics: why species and route matter

A validated LC-MS/MS study in rats reported measurable exposure after intravenous and oral administration, with mean oral bioavailability of 38.4%. Awosemo et al., Journal of Pharmaceutical and Biomedical Analysis (2021)

The 2024 mouse study produced a very different oral result. Estimated oral bioavailability was 3.5%, while controlled subcutaneous administration produced much greater systemic and tissue exposure. The authors attributed the low oral exposure in mice to limited intestinal absorption and substantial metabolism during the first pass through the liver. Babula et al., Diabetes, Obesity and Metabolism (2024)

The same investigators also identified high metabolic clearance in mice and activity involving another enzyme, monoamine oxidase A (MAO-A), as areas requiring further compound optimization. The rat and mouse values should not be blended into a single expected number. Together, these observations demonstrate why researchers must characterize exposure and selectivity in the species, route, formulation, and salt form actually being studied.

In Plain English

The amount of a compound that reaches circulation can differ dramatically between species and delivery methods. A result in rats cannot simply be assumed to apply to mice, and neither can be assumed to apply to humans.

This variability does not erase the biological findings. It tells researchers that pharmacokinetics and target engagement must be confirmed in each experimental model.

What makes 5-amino-1MQ a compelling research compound?

A defined molecular target NNMT activity can be measured directly.
A practical marker of target engagement A reduction in 1-MNA can help show that the pathway was affected.
A biologically connected mechanism NNMT links nicotinamide metabolism with NAD+ salvage and methyl chemistry that depends on SAM.
Findings across multiple research areas Adipocytes, liver metabolism, body composition, aged muscle, muscle regeneration, and performance of ischemic muscle have all been investigated.
A growing preclinical record Results have accumulated across cell systems and several rodent models rather than relying on a single experiment.
In Plain English

Researchers are interested because 5-amino-1MQ has a recognizable target, measurable pathway effects, and a growing set of positive animal findings. It gives laboratories a concrete way to ask whether changing NNMT activity can influence metabolism and tissue function.

What researchers should document

β€œ5-Amino-1MQ” may refer to the 5-amino-1-methylquinolinium cation or to a particular salt, commonly the iodide or chloride form. The salt and free cation have different formula weights, so reproducible work should identify the exact material and the basis on which concentration or mass is reported.

  • Chemical identity, counterion, purity method, and analytical data for each lot
  • Vehicle, formulation, route, species, strain, sex, age, and study duration
  • Whether the reported mass is based on the complete salt or the active cation
  • Exposure measurements when available
  • Target engagement, such as changes in 1-MNA or NNMT activity
  • Appropriate vehicle controls, blinding, sample size, and statistical plan

These details are not administrative trivia. They determine whether results can be interpreted and reproduced.

A positive and scientifically responsible conclusion

5-Amino-1MQ has earned attention as a selective research compound focused on NNMT. The preclinical literature presents a coherent and encouraging pattern. It includes measurable NNMT target engagement in cells, favorable changes in adipocyte metabolism, positive findings related to body composition and the liver in obese mouse models, and expanding evidence in skeletal muscle and regeneration research.

At the same time, the responsible interpretation remains narrow. These studies support continued laboratory investigation of NNMT biology and 5-amino-1MQ as an experimental pathway probe. They do not establish human safety, efficacy, dosing, administration, or clinical utility.

That distinction does not diminish the compound’s scientific value. It defines it accurately. For researchers interested in metabolic regulation, pathways connected with NAD+, adipocyte biology, and muscle physiology, 5-amino-1MQ remains a notable subject that is being studied in increasing detail.

Selected references

  1. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat-diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141–152. doi:10.1016/j.bcp.2017.11.007
  2. Neelakantan H, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481–492. doi:10.1016/j.bcp.2019.02.008
  3. Sampson CM, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports. 2021;11:5637. doi:10.1038/s41598-021-85051-6
  4. Awosemo O, et al. Development and validation of LC–MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: Application to pharmacokinetic and oral bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis. 2021;204:114255. doi:10.1016/j.jpba.2021.114255
  5. Babula JJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024;26(11):5272–5282. doi:10.1111/dom.15879
  6. Liang R, et al. Identification of nicotinamide N-methyltransferase as a promising therapeutic target for sarcopenia. Aging Cell. 2024;23(9):e14236. doi:10.1111/acel.14236
  7. Dong G, et al. Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease. Physiological Reports. 2025;13(20):e70615. doi:10.14814/phy2.70615

For Research Use Only

Not for human or veterinary consumption. Not intended for diagnostic, therapeutic, or clinical use.

Back to blog